The two-day MoneyShow just wrapped up in Toronto after running from Friday (September 14) to Saturday (September 15).

The Investing News Network (INN) team attended day two of the MoneyShow and kept busy attending presentations and panel discussions during the Cannabis Investing Event portion of the conference.

Below we’ve put together some highlights from the conference. Scroll on to read more about what happened on the show floor and stay tuned for more in-depth articles on the various cannabis panels.

US Election 2020 and Cannabis

Investing in cannabis? Read what experts have to say about cannabis and the US Election!

MoneyShow Toronto

During the morning portion of the conference, Anthony Dutton, CEO, co-founder and director at Cannex Capital Holdings (CSE:CNNX), hosted a panel called Developing a High-value Portfolio of Multi-state Assets in the Cannabis Industry. Additionally, Steven Hawkins, president and CEO of Horizons ETFs, provided a general cannabis outlook for the public markets.

Despite his expertise and close eye on the cannabis market, Hawkins is unsure of the future after legalization in Canada. “We really do not know what will happen on October 17,” he said.

Hawkins added that although he doesn’t know how the market will shape up, it is sure to be different.

For the remainder of the panel, Hawkins discussed a variety of important sales and acquisitions within the Canadian cannabis industry. Horizons has benefited from the rapid rise of the market with the launch of two ETFs dedicated to following the industry.

“HMMJ’s growth has far exceeded our expectations as investors have strongly supported the sector in anticipation of Canada’s upcoming recreational marijuana legalization,” Hawkins said after the ETF crossed the C$1-billion mark.

The afternoon portion of the conference consisted of two important panel discussions that covered the Canadian cannabis industry.

Both the first panel, How Green is Green? Outlook on the Canadian Cannabis Market, and the second panel, Cannabis in Canada: What Investors Need to Know About the Changing Legal Landscape, were moderated by Jay Rosenthal, co-founder and president of Business of Cannabis, a research and media company focused on the cannabis market.

The first panel of the afternoon included:

  • Cam Battley, CCO of Aurora Cannabis (TSX:ACB,OTCQB:ACBFF)
  • Danny Brody, vice president, investor relations, at the Green Organic Dutchman Holdings (TSX:TGOD,OTCQX:TGODF)
  • Mark Noble, senior vice president, ETF strategy, at Horizons ETFs
  • Chris Wagner, CEO of Emerald Health Therapeutics (TSX:EMH,OTCQX:EMHTF)

After discussing how the cannabis industry may change following legalization, the panel went on to discuss the importance of cannabis being available to consumers in a multitude of forms.

The panel ended with a warning from Battley. He noted that there are far too many cannabis companies and said many of them will be weeded out in the next few years.

The final panel of the conference included:

  • Greg Engel, CEO of Organigram Holdings (TSXV:OGI,OTCQX:OGRMF)
  • Jessica Martin, vice president, public relations, at Invictus MD (TSXV:GENE,OTC:IVITF)
  • George Robinson, CEO of RavenQuest BioMed (CSE:RQB)

Don’t forget to follow us @INN_Cannabis for real-time news updates and stay tuned for more cannabis stories from the MoneyShow!

Securities Disclosure: I, Nicole Rashotte, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: Invictus MD is a client of the Investing News Network. This article is not paid-for content.

Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the appointment of Dr. Joel Moody, MD, MPH, DTM&H, as a medical and clinical advisor to the Company to assist in the expansion of clinical studies in Canada and the clinical data analysis on the ongoing U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.

“We would like to welcome Dr. Moody as a medical and clinical advisor to our team and we look forward to his contributions in our ongoing FDA Phase 3 clinical study as well as expanding our COVID-19 studies in Canada,” said Michael Frank, CEO of Revive. “Dr. Moody’s experience in clinical epidemiology, data analysis and research are key to our FDA Phase 3 study as we gather clinical data from patients enrolled.”

Keep reading... Show less

– FinCanna Capital Corp. (CSE:CALI) (OTCQB:FNNZF), based in Vancouver, BC today announced that Andriyko Herchak, CEO, will present live at on December 3 rd .

Keep reading... Show less

First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to support patients with posttraumatic stress disorder

Keep reading... Show less

Multi-year partnership designates BioSteel as new official sports drink of Philadelphia 76ers team, Training Complex, and the presenting partner of 76ers Training Camp

BioSteel today announced a multi-year deal with the Philadelphia 76ers, making the sports hydration company the official sports drink of the team. BioSteel will also serve as a partner of the Philadelphia 76ers Training Complex, and the presenting partner for 76ers Training Camp, which begins next week.

Keep reading... Show less

Achievements with Scalability and Compatibility Pave Way for Next Phase of Advancement

Codebase Ventures Inc. (“Codebase” or the “Company”) (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF) is excited to announce that the Company’s holding, Arcology, a cluster-computing powered AI blockchain ecosystem with unlimited scalability, has updated its working roadmap in response to its Testnet 1.0 results

Keep reading... Show less